I. INTRODUCTION
The U.S. Food and Drug Administration (FDA) plays a vital public health role. It oversees human and animal medical products, food, dietary supplements, cosmetics, products that emit radiation, and tobacco-regulating approximately 25% of the U.S. consumer economy 1 -and features prominently in many of Although all on-label uses of drugs also are associated with risks (and sometimes quite serious risks), 12 such off-label marketing is troubling to regulators and many public health advocates for various reasons. It is wellestablished that industry promotion-both to prescribers and directly to patients-influences prescribing practices. 13 Research also suggests that the majority of off-label uses lack strong scientific support, off-label uses not supported by strong scientific evidence are associated with significantly higher rates of adverse events than on-label uses are, and prescribers are often unaware that particular uses are off-label even when the benefits of those uses are unsupported. 14 Promoting off-label uses, therefore, may inappropriately increase prescriptions for off-label uses that have unfavorable, or unacceptably uncertain, risk-benefit ratios. 15 Indeed, scholars have asserted that the off-label promotion of certain products "has led to widespread patient morbidity and mortality." 16 12 For example, when Zyprexa, one of the antipsychotics promoted for use in older patients with dementia, is used on-label for the indications and populations for which it is approved, it is associated with serious and potentially fatal risks such as neuroleptic malignant syndrome (NMS). See, e.g., U.S. Food & Drug Admin., Approved Labeling for Zyprexa (Oct. 2016), https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/ 020592s068s069,021086s044s045,021253s057s058lbl.pdf [https://perma.cc/4SKU-SR8C]. 13 has not approved may eliminate important incentives for companies to study those off-label uses-meaning that the scientific evidence needed for prescribers (and the public) to understand whether a particular use is appropriate is never produced. 17 Notwithstanding these concerns, courts, increasingly, have seemed willing to find that the First Amendment protects a broader range of off-label promotion than FDA policies have typically permitted. In response, commentators have suggested various ways in which public health concerns might be reconciled (or not) with the constitutional limits on the FDA's authority. Some scholars and advocates have proposed changes to the FDA's requirements for product marketing to better align agency policies with recent First Amendment decisions and make the agency less vulnerable to constitutional challenges. 18 Others have questioned the assumptions that appear to underlie recent court opinions expanding industry's First Amendment rights, highlighting reasons why courts should decline to extend, or should walk back, protections for commercial speech in this area. 19 Possibly most troubling for those concerned about expanded protection for commercial speech, as discussed elsewhere in this Issue, courts' recent willingness to recognize First Amendment protection for off-label promotion of approved drugs also may logically extend to protecting the promotion of unapproved drugs-which would de facto permit their sale, undermining the entire premarket approval scheme for new drugs. 20 This Article takes a different approach by exploring potential indirect consequences of recently recognized protections for off-label promotion. In United States v. Caronia, a high-profile 2012 case regarding off-label promotion, Judge Debra Ann Livingston's dissenting opinion cautioned that the majority's recognition of expanded protections for off-label promotion may have indirect effects-by causing the FDA's approval decisions, which must balance a drug's benefits against its risks, to "become[] very difficult or even impossible." 21 This Article argues that, as Judge Livingston suggested, protections for off-label promotion indeed might affect the FDA's decisionmaking in areas other than drug promotion, and analyzes precisely what those effects could be in light of the FDA's current statutory authority. 19 See, e.g., Micah L. 
"We fear that these developments could be the beginning of an FDA retreat from the FDCA's fundamental precepts . . . ."); Sharfstein & Charo, supra note 8, at 1795 (arguing that one company's off-label promotion lawsuit "challenged the US approach to drug regulation").
21 United States v. Caronia, 703 F.3d 149, 179 (2d Cir. 2012) (Livingston, J., dissenting); see also Cortez, supra note 20, at 140 ("Moreover, if the FDA knew that once a drug was approved, it could be legally marketed for any use, the agency might weigh the benefits and risks less charitably in the first instance."). As discussed in more detail in infra Part IV.A.2, the FDCA requires the FDA, in its approval decisions, to assess whether a "drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling." 21 U.S.C. § 355(d) (2012) . Based on this language, therefore, one might argue that the FDA cannot consider the risks of off-label uses in its approval decisions. When looking at the FDCA as a whole, however, there is also a case to be made that Congress did not intend to so limit the FDA. This statutory interpretation question is discussed in more detail in infra Part IV.A.2.
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The FDA, similar to other modern regulators, often relies on what scholars have called "information regulation"-"lighter-touch" regulatory tools, such as required disclosures or restrictions on marketing, that encourage the desired behavior or outcome, rather than directly mandating it through "command-andcontrol" tactics. 22 But if stripped of the ability to oversee off-label drug promotion, the FDA could begin to more strictly regulate the drugs themselves or industry's nonexpressive conduct, to satisfy its statutory obligations to ensure that a drug's benefits outweigh its risks. Moreover, this shift closer to commandand-control regulation may not be limited to decisions about drugs. Instead, such a shift could extend to any FDA decision-making that relies on a benefit-risk assessment. 23 This Article, therefore, examines potential indirect regulatory consequences of broader product promotion for the FDA's drug regulatory scheme, and also begins to explore the consequences for other areas in which FDA regulation relies on risk-benefit balancing, using new tobacco products as the example through which to undertake this analysis.
The FDA's authority to regulate new tobacco products is not the only area, other than new drugs, in which expanded protections for product promotion may indirectly affect the FDA's regulatory decisions. 24 Most clearly, expanded protections for postapproval promotion also may affect the FDA's regulation of devices-products for which FDA policies also prohibit off-label promotion, 22 See, e.g., Amanda Shanor, The New Lochner, 2016 WIS. L. REV. 133, 163-64 (2016) . 23 For some products that the FDA oversees, it does not employ a risk-benefit assessment similar to that applied to drugs. For example, the FDA does not generally assess the "benefits" of foods and cosmetics-instead, its mission is to help ensure that foods and cosmetics are safe and properly labeled. See and for which premarket authorization generally is based on a product's safety and effectiveness. 25 But this Article considers the example of the agency's new tobacco product authority to begin to examine how the indirect effects of increased protections for product promotion may extend beyond the context of medical products. 26 Ultimately, this Article suggests that, because the FDA regulatory regime is a complex, interconnected one, limiting or eliminating FDA oversight of certain aspects of product promotion could alter other regulatory decisions, at least at the margins. 27 Restricting off-label (and other kinds of) product promotion is a tool that the agency uses to manage the risks of what are often dangerous products. 28 Eliminating that tool from the agency's repertoire could push the FDA to look to other-frequently more paternalistic-options, such as product gatekeeping or restrictions on product use, to achieve its public health mission. This result, in turn, may mean more restrictions on how providers prescribe and dispense drugs, and fewer approvals for new drug and new tobacco productsneither of which is likely to be a desirable outcome. There is, thus, yet another reason for stakeholders to be concerned that loosening the FDA's oversight of product promotion will result in unwanted consequences.
To establish the context for these regulatory consequences, Part II provides an account of recent controversies regarding the off-label promotion of prescription drugs. Part III considers the reach of recent court decisions protecting off-label promotion, and argues that one possible outcome, at least in the foreseeable future, is that courts will conclude that the First Amendment protects a broader scope of off-label promotion of approved drugs than the FDA has historically permitted. Part IV then delves into the ways that the FDA's regulatory regime for drugs may be affected by such expanded protection for off-label promotion in two specific areas-agency decisions about whether and how to limit the use of new drugs in medical practice, and new drug approvals. Part IV also begins to consider how greater protection for product promotion may affect the FDA's regulation of other products for which it weighs risks and benefits, such as new tobacco products.
II. THE OFF-LABEL PROMOTION CONTROVERSY
To set the stage for considering the potential impact of expanded protections for the promotion of FDA-regulated products, this Part explains FDA policies on off-label promotion of drugs, and recent challenges to those policies. 25 See, e.g., FDA MEMO, supra note 17, at 6-7 (describing the FDA's policies on offlabel promotion of devices).
26 Infra Part IV.B. 27 Infra Parts IV and V. 28 Cf. FDA MEMO, supra note 17, at 2-3 (explaining that "[t]he separate weighing of benefit and risk for each intended use is critical" because evidence supporting safety and effectiveness in one context does not necessarily support safety and effectiveness of the same product in another context).
A. The FDA's Position on Off-Label Promotion
The FDA has broad authority over drugs sold in the United States. Under the FDCA, whether a product meets the definition of a drug such that it is subject to the FDA's requirements for drugs largely depends on the product's "intended uses." 29 Specifically, a product is a drug if it is "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease," or "intended to affect the structure or any function of the body." 30 Thus, the same substance may be a drug in some circumstances but not in others. For example, the FDA has explained "charcoal is the key ingredient in common products sold as fuel, a use outside FDA's jurisdiction, but charcoal products are drugs when intended for emergency treatment of poisoning." 31 And often the best piece of evidence demonstrating a product's intended use-at least for the purpose of determining whether a product meets the definition of a drug-is the manufacturer's representations about the product. 32 If a product is determined to be a drug, it is subject to the FDA's many requirements for drugs, including the agency's premarket approval authority for new drugs. New drugs cannot be sold in the United States without the FDA's approval. 33 When the FDA approves a drug, it approves that drug for the particular uses recommended in the drug's FDA-approved labeling. That is, the FDA approves a drug to treat a particular disease (or a particular stage of a disease), in a particular patient population, at a particular dose, and in a particular dosage form-all of which is reflected in the FDA-approved labeling. 34 However, once the drug is approved, medical practitioners generally may prescribe the drug for any purpose, including uses not in the drug's FDAapproved labeling. 35 Although practitioners are typically free to prescribe approved drugs offlabel, it has long been the FDA's position that a drug manufacturer's promotion of unapproved, off-label uses results in violations of the FDCA. 36 The FDCA does not expressly prohibit off-label promotion. 37 But the FDA interprets various FDCA provisions and the agency's implementing regulations such that off-label promotion is evidence that a drug is misbranded, and, in some cases, unapproved. 38 The FDCA prohibits marketing in interstate commerce misbranded or unapproved drugs, and both criminal and civil penalties are available to the government if a drug manufacturer violates those prohibitions. 39 One statutory rationale for the FDA's position, in short, is that under the FDCA and FDA regulations, if the intended use of an approved drug-as evidenced by the drug's labeling-is an unapproved use, the drug may be an unapproved new drug with respect to that off-label use. 40 Even though the FDA approves certain pieces of a drug's labeling, off-label promotion can be found in a drug's labeling because "labeling," as defined in the FDCA and FDA regulations, is a broad category. 41 It includes both the labeling that the FDA approves at the time a drug is approved, as well as many written, printed, or graphic promotional materials that the FDA does not approve before dissemination, including in some cases websites. 42 Additionally, and more commonly, off-label promotion may be evidence that a drug is misbranded in violation of the FDCA. False or misleading offlabel promotion in labeling or advertising misbrands a drug. 43 The FDCA also deems a drug to be misbranded if any of its labeling lacks "adequate directions" for all intended uses. 44 Drugs promoted for off-label uses, including through oral statements, lack such adequate directions for the unapproved use by definition, because their FDA-approved labeling will not include directions for the unapproved use. 45 Therefore, although off-label promotion itself is not expressly prohibited, in the FDA's view such promotion is evidence that drug manufacturers have violated the FDCA. 47 In determining whether speech is "commercial," courts generally consider whether the speech is advertising, whether it discusses a specific product, and whether the speaker has economic motivations. See, e.g., Bolger v. Youngs Drug Prods. Corp., 463 U.S. 60, 66-67 (1983) . Put more succinctly, courts examine whether the speech is "solely related to the economic interests of the speaker and its audience." United States v. Caronia, 703 F.3d 149, 163 (2d Cir. 2012). As Nathan Cortez has explored, in some circumstances it may be possible for speech by FDA-regulated industry to be noncommercial, and thus entitled to heightened protection. 52 First, if the regulated speech is false or misleading, or about unlawful activity, it does not qualify for protection. 53 If, however, "the communication is neither misleading nor related to unlawful activity," the government restriction survives judicial review only if the government has a substantial interest at stake, the government's speech restriction directly advances that substantial interest, and the government's restriction is no more extensive than necessary. 54 Although described as intermediate scrutiny, Central Hudson may be an increasingly difficult test for the government to satisfy. When courts consider mandated disclosures or government counter speech to be viable alternatives to directly restricting commercial speech, the government will face difficulty satisfying the fourth prong of the Central Hudson test-that the government's regulation be no more extensive than necessary. 55 Moreover, some commercial speech restrictions may be subject to even more exacting scrutiny than the Central Hudson test establishes. In Sorrell v. IMS Health, Inc., decided in 2011, the Supreme Court explained that commercial speech restrictions that are "content-based"-meaning the government chooses to regulate the speech "because of disagreement with the message it conveys"-are subject to "heightened scrutiny." 56 The Court did not further explain what such "heightened scrutiny" entails, beyond explaining that the government must at least show that it satisfies the Central Hudson test. 57 Government restrictions on commercial speech that is not false or misleading (or about an illegal product), thus, may face skeptical courts, whether those courts apply the intermediate scrutiny test from Central Hudson or the "heightened scrutiny" envisioned in Sorrell. 58 50 Sorrell v. IMS Health Inc., 564 U.S. 552, 582 (2011) (Breyer, J., dissenting). 51 See, e.g., Caronia, 703 F.3d at 163; Berman, supra note 19, at 541. 52 Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n, 447 U.S. 557, 566 (1980). 53 Id. at 563-64. 54 Id. at 564. 55 See, e.g., Berman, supra note 19, at 508-09. 56 Sorrell v. IMS Health Inc., 564 U.S. 552, 565-66 (2011). 57 Id. at 572. 58 See, e.g., Berman, supra note 19, at 508 ("In the years following Central Hudson, the test has begun to look more like strict scrutiny . . . .").
Recent Applications to the FDA's Position
Since first recognizing that the First Amendment protects commercial speech in the 1970s, the Supreme Court and lower courts have considered commercial speech protections for various types of prescription drug marketing, and stakeholders have had success challenging some legal restrictions on drug promotion. Some of these successes have come in the context of off-label promotion specifically, as when a federal judge concluded that the FDA's conditions under which drug manufacturers could distribute peer-reviewed and reference literature on off-label uses violated manufacturers' First Amendment rights. 59 And others have come in the context of drug advertising more generally, as when the Supreme Court concluded in Sorrell v. IMS Health, Inc. that a Vermont law restricting the use of prescriber-identifying information for drug marketing "[was] contrary to basic First Amendment principles." 60 Yet, until recently, these cases did not seem to seriously challenge the FDA's position that off-label promotion leads to violations of the FDCA. Indeed, the government continued to successfully bring enforcement actions against companies and executives engaged in off-label promotion, often obtaining enormous payouts as part of settlements. For example, in 2009, Eli Lilly paid approximately $1.4 billion to settle a case involving off-label promotion of its antipsychotic drug, Zyprexa, as a treatment for dementia. 61 This promotion resulted not only in a violation of the FDCA-at least in the government's view-but also involved serious public health concerns. In addition to being unproven to be effective for dementia, Zyprexa is associated with an increased risk of death when used in elderly patients with dementiarelated psychosis. 62 The landscape for the FDA to enforce its position on off-label promotion, however, seems to be changing. Scholars have argued that First Amendment jurisprudence is increasingly coming into conflict with the modern regulators' reliance on information regulation rather than command-and-control tactics. 63 Consistent with this trend, in recent years the FDA has faced challenges to its position on off-label promotion on several occasions.
In 2009, the FDA faced a lawsuit that broadly challenged the agency's de facto ban on off-label promotion. The complaint, filed by Allergan, sought a decision permitting the company to distribute truthful and non-misleading information about the use of Botox for common off-label indications such as juvenile cerebral palsy and headaches. 64 Notably, regulators in other countries had already approved Botox for treating juvenile cerebral palsy, 65 and since the lawsuit, the FDA has approved Botox for chronic migraines. 66 The government, however, settled with Allergan in 2010 67 -thereby avoiding the First Amendment question. A few years later, the FDA was not as fortunate. In 2009, a jury found Alfred Caronia, a sales representative for a subsidiary of Jazz Pharmaceuticals (Jazz), guilty of a misdemeanor conspiracy to introduce misbranded drugs into interstate commerce based on Mr. Caronia's off-label promotion of Jazz's narcolepsy drug, Xyrem. 68 The facts of the case, in some respects, seemed sympathetic to the FDA's position. According to the Second Circuit, Mr. Caronia "plainly promoted the use of Xyrem" for "unapproved uses," ranging from insomnia to fibromyalgia to Parkinson's disease. 69 Moreover, despite the serious risks associated with Xyrem, including death-for which the FDA had required a black box warning and a special risk mitigation program for the drug-Mr. Caronia asserted that Xyrem is "a very safe drug." 70 Nevertheless, in 2012 a two-judge majority of the Second Circuit overturned Mr. Caronia's conviction on First Amendment grounds. As a preliminary matter, despite the FDA's usual position that off-label promotion is evidence of a violation of the FDCA rather than a violation in and of itself, 71 the majority determined that Mr. Caronia was prosecuted for his speech alone. 72 The majority did not consider Mr. Caronia's speech to be evidence of the drug's intended use because the government's argument at trial suggested that "Caronia's speech was itself the proscribed conduct." 73 The majority then considered the appropriate standard for review. As in Sorrell, in which the Supreme Court concluded that Vermont's restrictions on using prescriber-identifying information for drug marketing were content based and thus subject to "heightened scrutiny," the majority concluded that heightened scrutiny was warranted for Mr. Caronia's prosecution. 74 But the majority nevertheless applied the four-part test from Central Hudson because if a government action cannot survive intermediate scrutiny under Central Hudson, it also cannot survive heightened scrutiny.
Because the government failed to argue that Mr. Caronia's statements were false or misleading at trial, the majority presumed that his statements were truthful and non-misleading, and focused on the last three factors of the Central Hudson test. 75 Although the majority concluded that the government had a substantial interest in protecting the public's safety and health, it determined that prosecuting Mr. Caronia did not directly advance that interest because offlabel prescribing is generally permitted, and, thus, restricting information about such prescribing in fact might be detrimental to the public health. Moreover, the court identified a number of "less-speech restrictive" regulatory options available to the government, including distributing its own views about off-label uses, or even prohibiting off-label use itself. 76 Accordingly the majority concluded that even if Central Hudson's "less rigorous intermediate test" applied to the government's action, prosecuting Mr. Caronia for his off-label speech violated his First Amendment rights. 77 
III. CARONIA'S IMPACT
It is, perhaps, an understatement to say that public health and FDA law scholars have identified Caronia as an important ruling. 78 But roughly five years later, the decision's impact on FDA oversight is not entirely clear in part because the government declined to appeal the decision. 79 In the absence of a Supreme 74 Id. at 163-64. 75 Id. at 166 n.10. There was, however, a strong argument that at least some of Mr. Caronia's statements were false or misleading, and therefore not protected under the First Amendment. For example, Mr. Caronia described Xyrem as a "very safe drug." Id. at 157. But Xyrem is associated with serious risks, including the risk of death, and is a Schedule III controlled substance that presents a risk of misuse. 
A. It Changes Nothing
One possibility is that Caronia will not lead to meaningful changes in the FDA's regulation of advertising and promotion. Shortly after Caronia was decided, the director of the FDA's Office of Prescription Drug Promotion (OPDP) explained that Caronia would not "significantly affect" the agency's off-label promotion policies because the decision did not address the constitutionality of using off-label promotion as evidence of intended use, nor did it strike down any provisions of the FDCA or FDA regulations. 80 In 2016, in United States ex rel. Polansky v. Pfizer, the Second Circuit seemed to partly endorse the OPDP director's view of the Caronia decision, albeit in dictum. 81 Polansky was a False Claims Act case that focused on the questions of whether a manufacturer engaged in off-label marketing, and, through that marketing, improperly induced federal and state health care programs to pay for the drug. 82 The allegedly off-label promotion involved marketing Lipitor, a drug that the FDA approved for lowering cholesterol, for that use but for a purportedly inappropriate patient population. The court ultimately concluded that Lipitor had not been marketed off-label, but also noted in a footnote that "Caronia left open the government's ability to prove misbranding on a theory that promotional speech provides evidence that a drug is intended for a use that is not included on the drug's FDA-approved label." 83 Consistent with this view, in January 2017 the FDA published a lengthy memorandum documenting its public health rationale for its policies on offlabel promotion as well as various arguments that those policies comport with the First Amendment. 84 Among other things, the memorandum asserted that the First Amendment does not prohibit the use of product promotion as evidence of intended use. 85 The agency cited Polansky, as well as numerous other cases in which courts have reached the conclusion that product promotion may be used to determine whether a wholly unapproved product is a drug subject to relevant FDA requirements. 86 Additionally, some courts outside of the Second Circuit have expressly declined to follow Caronia. For example, one judge in the Eastern District of California explained that the idea that off-label promotion is permissible "has gained little traction" in the Ninth Circuit. 87 One also might (or might not) point to the fact that the FDA has yet to revise its drug promotion regulations, 88 and the government's continued ability to settle at least some off-label promotion cases for large amounts, 89 
B. It Changes Everything
A second possibility-and the one most concerning for many scholars and public health advocates-is that Caronia will be interpreted broadly such that it undermines the benefits of the FDA's premarket approval system, or wholly dismantles the system. 91 Indeed, one high-ranking FDA official was reportedly "horrified" when the Second Circuit decided Caronia in 2012, possibly in recognition of the potential for the decision to broadly disrupt drug regulation. 92 As the FDA has explained, permitting broader off-label promotion may diminish industry incentives for studying and obtaining approval for new uses of drugs. 93 This result would be troubling because an important function of FDA regulation is to incentivize the production of scientific knowledge about medical products. 94 The fears that the entire drug approval system will be undermined stem from concerns that Caronia will be interpreted to significantly limit, or eliminate altogether, the FDA's ability to rely on off-label promotion as evidence of violations of the FDCA. As Robertson argues in his article in this Issue, such an interpretation of Caronia could extend to the promotion of unapproved drugs, including obviously ineffective and fraudulent products. 95 That is, if courts extend Caronia to conclude that product promotion cannot be evidence of intended use in the postapproval context, courts logically could conclude that product promotion, likewise, cannot be evidence of intended use in the preapproval context. 96 This would present a significant obstacle to the FDA regulation of drugs because often the FDA uses the manufacturer's speech to demonstrate that the product falls within the definition of a drug-meaning the product is intended to address disease or affect the structure or function of the body-and the government alleges that the manufacturer has violated the law by selling an unapproved new drug. 97 96 See id. at 1042; see also Cortez, supra note 20, at 140 (explaining that eliminating the prohibition on off-label use "would also draw into question not only the century-old intended use doctrine, but also the very definitions of 'drug' and 'device,' which also depend on intent"). . A drug's intended use is also critical the unapproved products context, the FDA may not be able to enforce requirements for premarket approval, essentially eliminating the FDA's gatekeeping role for drugs. 98 And that result would also reach far beyond the FDA context, disrupting other regulatory regimes that rely on speech as evidence of intent. 99 That said, none of the decisions following Caronia-in the Second Circuit or elsewhere-have extended Caronia to unapproved products. 100 There may be practical reasons for this. As Robertson notes in his article, even if the logic of Caronia can extend quite far, "courts can and do draw arbitrary lines." 101 Although the FDA frequently relies on speech as evidence in cases regarding wholly unapproved drugs, courts may be disinclined to extend Caronia's rationale to that context because it is expressly stated in the FDCA that selling unapproved new drugs is illegal. 102 Given the explicit statutory prohibition, it may be easier for courts to agree with the FDA's argument that the agency is prohibiting the conduct of selling an unapproved drug-not the promotional speech-and is simply using the speech as evidence that the product is a new drug under the law. 103 Although it is the FDA's position that selling approved drugs that have been promoted for off-label uses likewise is conduct that violates the FDCA-and there is a strong argument supporting the agency's to demonstrating that the product is a "new drug" subject to the requirements for premarket approval. 103 There are times when the government proceeds against the manufacturer of a wholly unapproved drug on the theory that the company is violating the law by selling a misbranded or adulterated, rather than an unapproved, drug. For example, the FDA has jurisdiction over a drug only when it (or its components) move in interstate commerce. 21 U.S.C. § § 321(g), 331. This limitation on the FDA's authority is rarely relevant because modern product production generally involves at least product components crossing state and international borders. But in a case that involved an unapproved autologous stem cell therapy, one issue was whether, and when, the product had traveled in interstate commerce such that the FDA had jurisdiction over it. See United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1320 (D.C. Cir. 2014). The FDA has more flexibility in finding evidence of the needed nexus with interstate commerce for misbranded and adulterated drugs than it does for unapproved drugs. See 21 U.S.C. § 331(a), (c), (k). Thus, in the case of this unapproved stem cell therapy, the evidence supporting the government's allegations of misbranding and adulteration violations was likely stronger than the evidence that would have supported allegations of unapproved drug violations. And, in fact, the government's theory was that the stem cell therapy was misbranded and adulterated. See, e.g., Regenerative Scis., 741 F.3d at 1318. But even when the government proceeds against the manufacturer of a wholly unapproved new drug on a theory that the drug is misbranded or adulterated, courts have been willing to accept company statements as evidence of intended use, see, e.g., id.-perhaps because it is well-accepted that unapproved new drugs violate the law, even if the government's theory does not rely on a lack of approval. position 104 -it is a much more nuanced statutory interpretation argument than a claim that selling wholly unapproved new drugs violates the law. Because of the complicated statutory interpretation underlying the FDA's position on off-label promotion, it may be more difficult for the government to persuade judges and juries that selling products that are promoted off-label is illegal conduct and offlabel promotion is being used solely as evidence as intent.
C. It Changes Some Things
Because courts, thus far, have declined to extend Caronia to the context of unapproved products, a third possibility, and perhaps the most likely scenario for the foreseeable future, is that Caronia will affect FDA oversight by broadening product promotion, but only for FDA-approved products. There are some practical signs that Caronia has made the FDA cautious in its regulation of prescription drug advertising and promotion without completely halting enforcement. For example, the FDA sent relatively few warning and untitled letters regarding prescription drug promotion in recent years-sending only 9 in 2014, 105 9 in 2015, 106 and 11 in 2016, 107 compared with 31 in 2011, 108 the year before Caronia was decided, 51 in 2010, 109 and 41 in 2009. 110 Although there are many reasons why the FDA may have sent fewer letters in this area in the last several years, one possibility is that the FDA is currently exercising its enforcement powers conservatively to avoid First Amendment challenges. 111 Additionally, the agency has made public that it is in the process of reexamining its off-label promotion policies. The FDA hosted a public meeting in November 2016 to obtain input on off-label promotion, 112 at which commenters raised constitutional questions about the agency's policies. 113 The agency then published a sixty-three page memo detailing its public health interests in regulating off-label promotion and its current view of the First Amendment caselaw to provide additional information for interested stakeholders and solicit more public input. 114 Although it is not yet clear what result the agency's re-examination of its own policies will have, several cases that followed Caronia also suggest that the protections announced in Caronia may provide an avenue for broader promotion of approved products. In Amarin Pharma, Inc. v. FDA, a federal judge in the Southern District of New York (which, notably, is in the Second Circuit), relied on Caronia to enjoin the FDA from prohibiting Amarin from engaging in "truthful and non-misleading speech promoting the off-label use of [its drug] Vascepa." 115 The FDA approved Vascepa in 2012 to reduce triglyceride levels in adults with severe hypertriglyceridemia, a risk factor for coronary artery disease. 116 Amarin then sought FDA approval for use in a broader patient population-patients with triglyceride levels that were persistently high, but did not amount to severe hypertriglyceridemia. The FDA denied approval for the broader indication, and in its letter to the company, reminded Amarin that Vascepa "may be considered to be misbranded" under the FDCA if marketed for the sought-after, but still unapproved, indication. 117 Amarin then went to court to seek an injunction that would prevent the FDA from prohibiting the company from making "truthful and non-misleading" offlabel statements about Vascepa. 118 Finding for Amarin, the federal judge concluded that the FDA may not bring an enforcement action based solely on truthful promotion about an approved drug. 119 Amarin, agreeing, among other things, not to appeal the decision. 120 Additionally, several months after the Amarin decision, the agency settled another off-label promotion lawsuit brought in New York by Pacira Pharmaceuticals, Inc. 121 The FDA's decision to settle with Amarin and Pacira indicates that Caronia, in fact, is affecting FDA regulation of off-label promotion. These settlements suggest that the agency was not confident in its ability to prevail in further litigation, at least in the Second Circuit. But that Caronia is binding only in the Second Circuit does not necessarily significantly limit its impact. Amarin and Pacira demonstrate that, whenever the FDA threatens to enforce its de facto prohibition on off-label marketing, companies may elect to file a complaint seeking an injunction in a federal court in the Second Circuit, which will be bound by Caronia. 122 Additionally, several district courts outside of the Second Circuit have followed Caronia's reasoning to conclude that truthful, nonmisleading off-label promotion about approved products is permissible, which suggests that Caronia may be persuasive in other jurisdictions. 123 Accordingly, as a practical matter, Caronia-combined with Amarin, Pacira, and the other subsequent cases suggesting that Caronia was not a fluke-may substantively change the pharmaceutical industry's advertising and promotion strategies. 120 One might note that the circumstances of Caronia, Amarin, and Pacira (and Allergan) may have been unusually unfavorable for the FDA. 124 As already noted, in Caronia the government failed to argue that the speech at issue was false or misleading. Amarin, likewise, involved unusual circumstances. 125 The active ingredient in Vascepa is icosapent ethyl, which is an omega-3 fatty acid similar to an ingredient in fish oil products that are marketed as dietary supplements. 126 Those supplements may be legally marketed to persons without severe hypertriglyceridemia, 127 and the inconsistent treatment of the productseven though required by the differing regulatory regimes that Congress has established for drugs and dietary supplements-seemed not to sit well with the deciding judge. 128 Pacira similarly involved a potentially uncommon situation in which one contested issue was what the label encompassed-meaning the dispute between the company and the agency focused in part on whether the promotion was on-or off-label. 129 Amarin and Pacira also pre-dated the Second Circuit's Polansky opinion, in which the court commented that Caronia does not foreclose the possibility that the government could use off-label promotion as evidence of intended use needed to prove a violation of the FDCA. 130 But in Polansky, the Second Circuit concluded that off-label promotion had not taken place-meaning it did not address the circumstances of Amarin and Pacira, nor did it decide the question of when off-label promotion may, or may not, be used as evidence of violations of the FDCA. 131 Moreover, the Second Circuit seemed to endorse a definition of off-label promotion that may be narrower than the FDA's definition. 132 The court identified a "distinction" between promoting a drug for diseases and conditions for which it is unapproved, and promoting a drug for its approved purpose but to populations "neither specified nor excluded in the label." 133 The FDA may not draw a similar distinction. 134 Thus, it is not clear how helpful 124 In Allergan, as noted above, the company sought assurances that it could market Botox off-label for numerous indications including some that were either approved in other countries or ultimately approved by the FDA. 134 The FDA's view is that promoting a drug for an unapproved patient population constitutes off-label promotion. See, e.g., Cortez, supra note 20, at 124 ("Off-label use can range from conspicuous (prescribing a product for an unapproved medical condition or patient group) to more subtle (prescribing beyond the approved dosage, duration, or any other parameter set forth in the approved labeling)."). But at issue in Polansky was whether Polansky would have been for the government, had it been decided before Amarin and Pacira. Taken together, Caronia and subsequent cases seem to have affected the extent to which the FDA can enforce its policies on off-label promotion, at least in certain circumstances, 135 leading to the possibility for broader promotion of approved drugs than the FDA has historically permitted.
IV. EXPLORING INDIRECT CONSEQUENCES
Even if protections for off-label promotion are limited to claims about approved products, we are likely to see broader prescription drug promotion than the FDA has historically tolerated. However courts define what constitutes "truthful and non-misleading" claims about approved prescription drugs, and however the FDA may revise its promotion policies, the result is likely to be one that permits a wider range of promotion. 136 One question that Caronia, thus, raises is how broader drug promotion might change other areas of FDA regulation under its existing authority, particularly in ways that may not be as vulnerable to First Amendment challenges. 137 And because First Amendment protections for drug promotion are likely to also apply to other products within the FDA's jurisdiction, this question is not limited to prescription drug regulation. Instead, such indirect effects might occur in any area in which the FDA weighs risks and benefits and in which broader product promotion can alter that balance of risks and benefits.
This Part takes up the question of what Caronia and its progeny's indirect effects may be, arguing that limiting the FDA's ability to regulate product promotion may increase the risks of the products and thus alter the way that the FDA implements its authorities that are linked to a weighing of risks and benefits. 138 It first explores the possible indirect consequences of Caronia on the drug, in fact, was promoted for an unapproved patient population, with the court ultimately concluding it was not so promoted. Polansky, 822 F.3d at 620. Therefore, it is not entirely clear whether the court meant to define off-label promotion more narrowly than the FDA does. 135 
A. The FDA's Regulation of New Drugs
This Part considers the consequences of expanded protection for off-label promotion for the FDA regulation of new prescription drugs, suggesting that it may lead to the FDA more frequently requiring risk mitigation programs for drugs and to the agency approaching approval decisions more conservatively. 139 To make this argument, it is helpful to first understand why off-label promotion a third example, the majority opinion in Caronia suggested that the FDA might choose to increase its own publicity efforts to counter any industry communications that are problematic in the agency's view. Caronia, 703 F.3d at 168. Indeed, the FDA clearly has the authority to communicate about the products that it regulates. See, e.g., 21 U.S. Particularly when information about risk is nuanced, as will often be the case for new drug and ENDS products, it is difficult to imagine that financially limited FDA publicity could overcome messages in sophisticated industry marketing with far greater resources behind it. 139 Cf. FDA MEMO, supra note 17, at 2 ("The separate weighing of benefit and risk for each intended use is critical because evidence establishing effectiveness in one setting . . . does not establish effectiveness of the same product in another setting . . . .").
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[Vol. 78:4 poses public health concerns. Put simply, one reason is that off-label promotion may increase the risks of a drug. 140 Some off-label uses are medically important, as the FDA itself has acknowledged. 141 For instance, off-label uses are important for certain subpopulations, such as children and pregnant women, because relatively few drugs are studied in, and approved for, those groups. 142 And in some areas of medicine, such as oncology, off-label uses of drugs may be the standard of care in part because the research moves more quickly than the FDA approval process can and the drugs may be particularly likely to be effective against more than the one type of cancer. 143 Nevertheless, broad off-label promotion can pose significant public health concerns. Research suggests that, even with the current limits on off-label promotion, over 70% of off-label prescriptions are for uses that lack strong scientific support. 144 (noting that "there may be a public health need to restrict some off-label uses of targeted therapies and TAB tests"). Despite the lack of strong evidence to support many off-label uses, insurers may pay for such off-label prescriptions, likely for several reasons, including that it can be difficult for insurers to distinguish between supported and unsupported offlabel uses, and between off-label and on-label uses. See, e.g., Abbott & Ayres, supra note higher rates of adverse events than on-label uses, and physicians often are unaware that particular drug uses are off-label even when those uses lack scientific support. 145 Additionally, many of the FDA's off-label-related enforcement actions have revealed concerning conduct in which drug companies have promoted risky off-label uses. 146 Assuming that off-label promotion effectively increases off-label prescribing, 147 such promotion, thus, may cause an increase in these riskier uses of drugs.
Because there is debate about what are, in fact, truthful and non-misleading statements about drugs, limiting protections to what courts determine to be truthful and non-misleading claims is not likely to address such public health concerns about off-label promotion. 148 Courts may be willing to conclude that truthful and non-misleading promotion, in at least some circumstances, includes promotion about uses that lack significant scientific support. Amarin provides an example. Amarin sought to market Vascepta for lowering triglyceride levels in patients without severe hypertriglyceridemia with a statement that Vascepa "may reduce the risk of coronary heart disease." 149 But several clinical trials conducted to study the link between lowering lipid levels and lowering the risk of cardiovascular disease were inconclusive. 150 Despite the lack of scientific support for asserting that a link between lowering lipid levels and the risk of cardiovascular disease exists, a federal judge concluded that Amarin's statement was permissible truthful and non-misleading promotion. 151 And Amarin's claim about Vascepta is, of course, technically true-absent definitive evidence, we could say that anything may, or may not, be linked with a reduction in cardiovascular disease. 152 The claim, however, in fact may be misleading, given that many likely understand the claim to be more definitive than it literally is, 146 See, e.g., supra notes 9-11 and accompanying text. 147 It seems fair to make this assumption. After all, increasing off-label uses of drugs is likely to be one, if not the only goal, of a company's off-label promotion, and research has demonstrated that drug promotion influences prescribing practices. See, e.g., Wazana, supra note 13, at 375. 148 See, e.g., Hey & Kesselheim, supra note 19, at 3. 149 See id. at 2. 150 See id. 151 Id. 152 Id.
and at the very least, the claim is uninformative. 153 This result in Amarin demonstrates how what courts deem to be "truthful and non-misleading" promotion may nevertheless include promotion about uses of drugs that lack strong scientific support-and are likely to be riskier. 154 The question, then, is how the FDA might address increased risks associated with drugs that are marketed off-label. This Part explores a few ways that the FDA could attempt to mitigate increased promotion-related risks of drugs, focusing on the FDA's authority to require Risk Evaluation and Mitigation Strategies (REMS) and its approval authority. In short, increased risks of drugs may alter the way that the FDA implements these authorities, possibly leading to undesirable policy consequences by restricting access to drugs or removing them from the market.
Regulating the Practice of Medicine Through REMS
In Caronia, the majority opinion noted that "less-speech restrictive" regulatory alternatives available to the FDA included "prohibit[ing] off-label use altogether" or capping the number of off-label prescriptions that physicians may write. 155 As others have argued, these suggestions seem "ludicrous" for several reasons. 156 With limited exceptions, the FDA generally does not have the statutory authority to directly regulate prescribing practices 157 and has faced vigorous political opposition when it has been perceived as wading into medical practice oversight. 158 Moreover, as already noted, the FDA recognizes that some off-label uses are medically valuable. 159 Thus, it is nearly impossible to imagine that the FDA would broadly prohibit all off-label uses (or cap the number of offlabel prescriptions a provider may write, which would do nothing to distinguish supported and unsupported uses), even if it had express statutory authority to do so.
But restrictions on off-label use are not unprecedented. Examples of federal limits on off-label use include the FDCA's prohibition on off-label prescribing of Human Growth Hormone (HGH) and the Controlled Substances Act's prohibition on prescribing certain controlled substances for "maintenance treatment" unless those drugs are approved for that indication. 160 States have also limited off-label prescribing of certain drugs through legislation and regulation, consistent with states' long-recognized authority to regulate medical practice pursuant to their police powers. 161 And it is not impossible to imagine that if-or when-expanded off-label promotion (and use) leads to increased risks associated with drugs, the FDA would make greater use of its authority to indirectly regulate medical practice through requiring Risk Evaluation and Mitigation Strategies (REMS) for prescription drugs. 162 REMS are, essentially, special risk mitigation programs for drugs that the FDA can require drug manufacturers to implement and that go beyond including warnings or other information in a drug's FDA-approved labeling. 163 The REMS may include, among other things, tools known as "elements to assure safe use" that require manufacturers to ensure that drug prescribers or dispensers have special training (e.g., about the risks of misuse and overdose associated with controlled substances), that the drug is dispensed only in certain settings (e.g., only in a hospital inpatient setting), or that certain tests results are documented before a drug is dispensed (e.g., a negative pregnancy test for a drug known to cause birth defects). 164 Although the FDA has not explicitly used REMS to prohibit all off-label uses of a drug, some REMS appear to significantly restrict off-label uses, or at least make them more 159 See, e.g., REPRINT GUIDANCE, supra note 141, at 6. 160 Zettler, supra note 35, at 456. 161 difficult. 165 For example, the REMS for Entereg-a drug approved to accelerate recovery after certain bowel resection surgeries 166 -requires the manufacturer to ensure that Entereg is only "dispensed in a hospital in patient [sic] setting that performs bowel resection surgery," thereby limiting the ability of providers to utilize this drug for off-label uses. 167 In this way, although it is drug manufacturers and not health care providers that are responsible for complying with REMS requirements, the FDA, nevertheless, can indirectly regulate offlabel uses. 168 The FDCA authorizes the FDA to require a REMS when the agency determines that one is necessary to ensure that the benefits of a drug outweigh its risks. 169 To the extent that broader off-label promotion and greater off-label use increase the risks of a drug, it, thus, is logical that the FDA would more frequently determine that a REMS is necessary to ensure a favorable benefitrisk ratio. In fact, in determining whether to require a REMS, the FDCA seems to broadly authorize the FDA to consider the risks of all off-label use in its REMS decisions. Specifically, the FDCA provides that the FDA should consider "any known or potential adverse events that may be related to the drug" without requiring an association with an on-label use. 170 Additionally, the FDCA includes in its definition of adverse drug experiences relevant to the FDA's REMS decision-making off-label uses-such as "abuse" and "overdose . . . whether accidental or intentional," as well as any adverse drug event "occurring in the course of the use of the drug in professional practice." 171 Consistent with this language, the FDA has required REMS that aim to mitigate risks associated with off-label uses of drugs, including risks posed to individuals who are not prescribed the drug. For instance, one purpose of the REMS for transmucosal immediate release fentanyl products, which are powerful painkillers, is to "[prevent] accidental exposure to children and others for whom [the drugs are] not prescribed." 172 REMS for Juxtapid, a cholesterol-lowering medication approved for patients with an inherited form of high cholesterol known as homozygous familial hypercholesterolemia (HoFH), is to mitigate the risk of serious liver injury associated with the drug. 173 To accomplish this goal, the REMS aims to ensure that "JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with" HoFH; that is, the REMS appears intended to discourage off-label use of the drug in patient populations for which the benefitrisk ratio may not be favorable. 174 If broader product promotion increases risky off-label uses, it, therefore, would be consistent with the FDCA and the FDA's previous decisions for the FDA to more frequently require REMS to address those risky uses. Indeed, an increase in the agency's use of REMS may be just what the Caronia majority envisioned (although not precisely in those terms)-rather than regulate drug manufacturers' speech to address risks of off-label promotion, the agency ought to more strictly regulate the products themselves, or the prescribing and dispensing of the products. This, in some views, is what the First Amendment requires.
But the FDA already requires REMS relatively often-according to the Generic Pharmaceutical Association, the agency requires REMS for about 40% of the novel drugs that it approves 175 -and greater use of REMS (or greater use of the most restrictive elements in REMS) does not come without trade-offs. For instance, more REMS programs may create more opportunities for anticompetitive behavior. The FDA, lawmakers, and scholars have expressed concern that manufacturers of branded drugs use REMS to delay generic generic competition that can lower drug prices-may not be the optimal way to mitigate concerns about risky off-label uses. 183 Beyond issues of competition and drug pricing, REMS may also involve trade-offs in medical care. Although REMS can be valuable tools for mitigating the risks of drugs, they also may impose burdens on patient access as well as the health care system more generally. Congress recognized this possibility, and required that REMS have elements to assure safe use "not be unduly burdensome on patient access" and "to the extent practicable . . . minimize the burden on the health care delivery system." 184 If the FDA must more frequently rely on its REMS authority, rather than its off-label promotion policies, to mitigate the risks of off-label uses, patients, health care providers, and health care systems are likely to bear more of the load of that risk mitigation work. 185 Relatedly, increased use of REMS would mean greater FDA involvement with the regulation of medical practice. States have long been viewed as the primary regulators of medical practice. 186 But there is no constitutional bar on the FDA regulating in this space-the federal government could regulate medical practice under its commerce (and other) powers. 187 Additionally, given the FDA's express authority to require REMS, there is no statutory obstacle to increased FDA involvement in medical practice through REMS. 188 Indeed, courts have upheld FDA actions that, arguably, regulated medical practice, so long as the agency was acting within its statutory authority, 189 and FDA, or other federal, regulation of medical practice may be warranted in certain circumstances. 190 But heavier use of REMS, nevertheless, may lead to concerns about supplanting medical practitioners' judgments with those of the agency. Although the agency's assessment of how a drug should be used may be correct from a population health perspective, it may limit medical practitioners' discretion in individual cases in a clinically meaningful way. 191 Particularly when patients may increasingly seek autonomy over their health care decisions and desire more choices in their medical care, 192 influencing clinical care based on a public health policy goal, rather than an individual patient's best interests, may be politically challenging. 193 
Approval
In addition to increasing the prevalence of REMS, broader off-label promotion may have the effect of making the standard for new drug approval more difficult to satisfy, at least for marginal drugs. 194 New drugs may not be sold in the United States until the FDA approves them as safe and effective, and the FDA may withdraw approval of a previously approved drug if it no longer meets that approval standard (among other reasons). 195 The FDA has long interpreted the safety and effectiveness standard for drug approval to mean that a drug's benefits outweigh its risks. 196 To help ensure that the benefits of a drug outweigh its risks, the FDA can take a number of steps to monitor and mitigate a drug's risks post-approval, including requiring warnings in a drug's labeling, patient-specific labeling known as medication guides, postapproval studies and clinical trials, and REMS (as discussed above). 197 The agency also conducts ongoing monitoring of the safety of approved drugs through an active postmarket risk assessment system and reported adverse events. 198 FDA restrictions on prescription drug promotion, including on off-label promotion, are another tool for the agency to mitigate the risks of a drug. 199 The FDA's policies on drug promotion are intended, among other things, to help ensure that accurate information is disseminated for safe use of the drugs. 200 Thus, if the FDA's ability to oversee drug promotion is significantly limited, that may affect how the agency views a drug's safety for the purpose of weighing its risks and benefits in approval decisions.
Of course, whether broader off-label promotion, in fact, could affect the FDA's approval decisions depends on whether the FDCA permits the FDA to deny (or withdraw) approval based on the risks associated with off-label uses. One might argue that the FDCA does not authorize the FDA to consider the risks of off-label use in these decisions. This is because the statute provides that the FDA will approve a drug when, among other things, the manufacturer shows that the "drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling." 201 Although the statutory interpretation question deserves a deeper analysis than this Article can provide, it is worth noting that this statutory language cannot be considered in a vacuum, divorced from the rest of the FDCA. Considering the current language of the FDCA as a whole, 202 there are strong signs that Congress did not intend the FDA to limit its evaluation of a drug's safety to risks associated with on-label uses, including in the context of approval and withdrawal decisions. 203 One example comes from the requirements for reporting safety-related information to the agency. As part of a new drug application, a company must submit, "full reports of investigations which have been made to show whether or not [a] drug is safe for use," 204 and after approval companies must also submit to the agency "adverse drug experience information." 205 Neither reporting requirement is limited to information about the risks of on-label uses. 206 That information about the risks of off-label uses is required to be submitted suggests that the FDA ought to use that information in its benefit-risk evaluations.
As another example, the changes to the FDCA made in the recently enacted 21st Century Cures Act further bolster the argument that Congress generally intends the FDA to consider a broad range of evidence in its approval decisions. The 21st Century Cures Act explicitly authorizes the agency to consider "real world evidence" and "patient experience data" in certain approval decisions. 207 Both of these are forms of evidence that may include information on uses that deviate from those recommended in a drug's current or proposed labeling.
As a final example, as discussed in Part IV.A.1., Congress has authorized the FDA to consider the risks of off-label uses for the purpose of requiring a REMS. 208 A REMS may be required when necessary to ensure that the benefits of a drug outweigh its risks. 209 In other words, the FDA may require a REMS when necessary to ensure that a drug satisfies the approval standard. 210 It, therefore, may be illogical to conclude that Congress intended the FDA to consider the risks of off-label uses when requiring REMS, but not when making approval decisions-particularly in light of the other evidence that Congress may not have intended to so limit the FDA. 211 Moreover, as a practical matter, the FDA appears to consider the risks of off-label uses as part of its benefit-risk evaluations for approvals and withdrawals, at least in certain circumstances. In discussing the FDA's role in addressing the opioid crisis, the FDA Commissioner and the director of the FDA's Center for Drug Evaluation and Research explained that, "[w]henever FDA assesses the benefits and risks of a product, it must make certain that its decision making is based on all of the available information." 212 For approval and withdrawal decisions about opioids, this means that the FDA must consider how opioids are actually used, including when that use deviates from the FDAapproved labeling. 213 Although opioid misuse and overdose is a particularly pressing and highprofile public health problem that may make it an unusual case, the FDA also seems to have considered the risks of off-label uses in its approval and withdrawal decisions in other contexts. One example is a 2011 FDA action on acetaminophen, an active ingredient in many prescription painkillers, such as Vicodin, and over-the-counter painkillers, such as Tylenol. 214 Acetaminophen is associated with a risk of serious liver injury and is a leading cause of acute liver failure in the United States. 215 After many years of attempting to address the risk of liver damage associated with acetaminophen through other means, the FDA published a Federal Register Notice announcing that the FDA would withdraw approval of prescription acetaminophen products with more than 325 milligrams of the ingredient in a dosage unit (e.g., pill) if manufacturers did not voluntarily lower the amount of acetaminophen. 216 The agency's rationale for this withdrawal decision included the agency's concerns about the risks associated with patients taking more acetaminophen than recommended in the drug's labeling. 217 It, therefore, seems plausible that if the FDA anticipates that unsupported off-label uses will be more widely promoted and more widely prescribed, that may change the agency's benefit-risk calculus at the time of approval. 218 Imagine, for example, a drug that is demonstrated to be highly effective for weight loss, but also is associated with rare, but serious and even fatal, cardiovascular risks. Despite such serious risks, the benefits of such a drug might outweigh the risks for patients with obesity or severe obesity, because of the serious health risks associated with the conditions themselves. 219 But it also seems likely that an effective weight loss drug-even one associated with serious risks-would be appealing to many individuals, including those without obesity, because of cultural pressures to be thin. The FDA might be less likely to approve such a drug, even with a REMS, knowing it could be promoted off- Cir. 2008) ("Yet if a manufacturer's promise to the FDA to avoid speech about off-label uses is unenforceable, the FDA may respond by withholding any approval of drugs or devices that have questionable additional uses."). As a practical matter, this change in the agency's riskbenefit assessment might increase the amount, or change the kind, of data that the FDA views as necessary to satisfy the approval standard, which, de facto, may make the standard more difficult to meet. Cf. NAS REPORT, supra note 203, at 6-26 to -32 (recommending that the FDA consider a broad range of data in its approval decisions regarding opioids, including data about unapproved uses). 219 label, albeit "truthfully." Indeed, the FDA has explained that "[t]he separate weighing of benefit and risk for each intended use is critical" for the agency's approval decisions. 220 Making this scenario more convincing, the agency is not likely to be able to effectively mitigate its concerns about off-label promotion by obtaining commitments not to market from companies at the time of approval. Even in areas without First Amendment concerns, the FDA has faced challenges enforcing approval conditions once a product is on the market. For example, questions have been raised about the FDA's ability to enforce postmarket studies and clinical trials of drugs that the agency required or drug companies committed to conduct, and similar concerns have been raised about the enforcement of REMS requirements. 221 Relatedly, we might see an increase in the FDA withdrawing drug approvals. The FDA rarely uses its authority to formally withdraw approval of a new drug, 222 likely for various reasons. These include that withdrawing approval is "not normally desirable if some patients [a]re benefitting from the drug despite its risks" 223 and, as noted above, the FDA is authorized to require a number of less drastic means of mitigating drug risks after approval such as requiring REMS and warnings on drug labeling. 224 Additionally, the FDA does not often need to rely on its formal withdrawal authority because companies often voluntarily stop marketing drugs when faced with serious safety and effectiveness concerns. 225 Nevertheless, if broader off-label promotion does increase the risks of drugs, we might expect to see the FDA more frequently withdrawing approval of drugs, if its other risk mitigation tools prove unsuccessful. Again, imagine the effective weight loss drug associated with serious cardiovascular risks. Given its benefits for patients with obesity or severe obesity, a more plausible scenario than the FDA denying approval, might be the FDA withdrawing approval if, after marketing, it becomes apparent that the drug's risks, including the risks of off-label use, outweigh its benefits.
To be clear, there is debate about whether the FDA's current implementation of the approval standard strikes the right balance, with some researchers and commentators raising concerns that the FDA's approval standard is too lenient, 226 and others arguing that the FDA's standard for approval is too stringent. 227 This Article does not attempt to enter that debate. Rather, this Article suggests that whatever the appropriate interpretation of the drug approval standard is, increased protections for off-label promotion may make it more difficult for the FDA to implement that interpretation of the approval standard by removing one tool for the agency to mitigate a drug's risks after approval.
Additionally, regardless of whether the mechanism would be fewer approvals or more withdrawals after approval (or both), as with REMS such an outcome does not come without trade-offs. The practical result of fewer approvals or more withdrawals, of course, would be that there are fewer approved drugs available for patients. This result is undesirable for various reasons, including that patients who might otherwise have had available treatments-or more treatment choices-will not have them, and fewer drug approvals (or more withdrawals) may, in some instances, lead to less competition and higher drug prices. 228 There may also be other, less obvious, trade-offs to consider. For example, there may be transparency concerns about shifting more risk management to drug approval decisions because there, arguably, is little oversight of FDA decisions not to approve drugs. Companies rarely, if ever, challenge those decisions in court, and the FDA's letter explaining its reasons for denying approval-known as a "Complete Response Letter"-generally is not publicly available under current FDA policies. 229 Also, again similar to the REMS context, if the FDA becomes more conservative in its approval decisions, or more aggressive in exercising its withdrawal authority, the agency is likely to face political pressure. Indeed, in recent years, there have been instances of controversial drug approval and withdrawal decisions during which the FDA faced intense pressure. One example was the FDA's 2016 decision to approve Exondys 51-a treatment for Duchenne Muscular Dystrophy-despite slim support for its efficacy, after patient advocates conducted a vigorous campaign in favor of the drug's approval. 230 As another example-and one in which the FDA made a decision different than the one sought by many patient advocates, some of whom protested outside the agency-in 2011 the FDA withdrew approval of the breast cancer indication for Avastin after postapproval research failed to confirm a clinical benefit associated with its effect on a surrogate endpoint. 231 With increased interest in patient-focused drug development (and sophisticated, sometimes industry-funded, patient advocacy organizations), 232 such pressures are likely to increase, especially if the approval standard appears to become more difficult to satisfy.
Although there are many open questions about the risks and benefits of ENDS for users and exposed nonusers, and the FDA will evaluate the merits of each product individually, researchers have suggested that we can draw a few general conclusions. Mainly, ENDS appear to be less harmful than traditional cigarettes, but also addictive, more harmful than no nicotine or tobacco exposure at all would be, and, so far, of uncertain value for influencing smokers to reduce or quit their cigarette consumption. 242 This suggests that in a marketing order analysis, the FDA might consider whether a specific ENDS product has attributes making it likely to be used by current smokers as a less harmful means of using nicotine, which would be a public health benefit. The FDA might also consider whether an ENDS product is likely to initiate tobacco and nicotine use among nonsmokers, which would pose a public health risk.
One way to assure the FDA that the smoking reduction benefits of an ENDS might be maximized, and the initiation risks minimized, would be to limit advertising either to current smokers (or a subset of current smokers) or to restrict the content of advertising in some way to encourage smokers to use the ENDS as a cigarette replacement. 243 In addition to potentially shaping the benefits of the products, ENDS product promotion could increase risks associated with the products, particularly in light of the evidence that tobacco marketing can be quite effective at initiating tobacco use among adolescents and young adults. 244 The FDA's benefit-risk evaluation of new tobacco products, as with drugs, thus might be shaped by how products are promoted and the agency's ability to oversee that promotion.
To the extent the First Amendment allows, the FDCA expressly authorizes the FDA to restrict tobacco product advertising and promotion to protect the public health. 245 In light of the fact that the FDA has had some success in defending the restrictions on tobacco product promotion imposed in the FDCA, the FDA may be better positioned to enforce restrictions on the promotion of approved tobacco products than it is to enforce its policies related to off-label promotion of drugs. For example, the FDCA requires that the FDA authorize the United States, causing roughly 480,000 deaths per year. 253 If the potential harm reduction benefits of ENDS and other novel tobacco products can be realized, such products could have a significant, positive impact on the public health by reducing smoking-related death and disease, and fewer products on the market may lessen that impact.
V. CONCLUSION
This Article suggests that the impact of recently recognized protections for off-label promotion-even if limited to what courts deem to be truthful and nonmisleading promotion about approved products-could affect FDA oversight outside of its product-promotion regulatory regimes. This effect is not limited to the context of medical products. Broader product promotion may alter any FDA regulatory decisions that involve weighing product risks and benefits, at least at the margins, because such promotion may increase the risks associated with the products. This, in turn, may lead to more limited access to FDAregulated products, which is not likely to be a desirable outcome for any stakeholders.
Although an undesirable policy outcome cannot trump protections for offlabel promotion grounded in the First Amendment, there may be creative, practical steps that the FDA and other stakeholders could take to mitigate potential indirect effects of off-label use. One possibility is that the FDA could explore ways that it might cooperate with other stakeholders that influence how drugs are used to mitigate the risks of unsupported off-label uses. 254 Perhaps most obviously, health insurers are stakeholders that can shape how prescription drugs are used-if insurers will not pay for particular uses, those uses are likely to be reduced or eliminated. 255 Moreover, regardless of the steps that the FDA and other stakeholders might take, this Article may provide another reason for courts to take seriously the government's position that it has a substantial interest in regulating off-label promotion, and to give that interest significant weight in First Amendment analyses.
